



## ***NEWS RELEASE***

FOR IMMEDIATE RELEASE

Contact: Ronald C. Trahan, APR, President, Ronald Trahan Associates Inc., +1-508-816-6730

### **Stentys drug-eluting *self-expanding* coronary stent shows 4% restenosis in complex lesions**

**Long-term follow-up data in Stentys DES and BMS clinical study shows superior results in the treatment of bifurcations**

PRINCETON, N.J., and PARIS, Feb. 15, 2010—Medical device pioneer **Stentys** announced today that the complete ‘**OPEN-I**’ clinical study was presented by **Stefan Verheye, M.D., Ph.D.**, at the **Joint Interventional Meeting (“JIM”) 2010** in Rome, demonstrating superior results in **60 patients (27 Stentys drug-eluting stents and 33 Stentys bare-metal stents)** who were followed-up angiographically after six months.

“These clinical results suggest very promising benefits for patients,” said **Stefan Verheye, M.D., Ph.D.**, Department of Cardiology, Middelheim Hospital, Antwerp, Belgium. “We had already demonstrated that the *self-expanding* and *disconnectable* Stentys platform ensured optimal wall apposition and easy access to side branches. We can now confirm that the addition of a drug coating eliminates the need for reintervention.”

“These data fortify our conviction of the indisputable superiority of Stentys self-expanding and drug-eluting stents over balloon-expandable DES for the treatment of complex cases,” added **Gonzague Issenmann, CEO and co-founder of Stentys**. “We are actively pursuing our clinical program, particularly in the treatment of Acute Myocardial Infarction, to also prove the superiority of the Stentys technology in this additional group of patients.”

#### **About Stentys**

Based in Princeton, N.J., and Paris, [Stentys](#) intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. The Company announced in December 2009 that it has started enrolling patients in the randomized **APPOSITION II** clinical trial to compare the Stentys *self-expanding* stent against conventional stents in treating AMI patients, looking specifically at stent apposition and adaptation to vessel growth. Stentys was co-founded by [Gonzague Issenmann](#) and [Jacques Séguin, M.D., Ph.D., founder of CoreValve](#), which was acquired last year by Medtronic for \$700 million plus earn-outs.

#####